Drugs / Autologous Engineered Urethral Construct
Autologous Engineered Urethral Construct
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03258658 | Aug 2026 → Dec 2028 expected | male reproductive system disorder, urethral stricture | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Engineered Urethral Construct | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03258658 ↗ |
| Modality | Cell therapy | “Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to...” NCT03258658 ↗ |